SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics
A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.
September 26, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of neurons
Multiple sclerosis
Study Casts Doubt on Benefit of Anti-CD20 Therapies in Multiple Sclerosis
New research has found that MS patients treated with anti-CD20 antibodies, such as Roche’s Ocrevus, do not experience significantly slower progression of disability.
September 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Abstract vector storm clouds with thunder hand drawn chaotic tangle of doodles.Sign bad weather,impending rain and storm,thunder rolls.Symbol stress,depression,psychosis,mental crisis personality,headache after suffering coronavirus.
Career Advice
How to Deal With a Toxic Co-Worker
Dealing with a toxic co-worker can be exhausting, and it can make your workplace more stressful. There are a few ways to make it easier, including developing healthy coping mechanisms and even talking it out with your colleague.
September 25, 2024
 · 
5 min read
 · 
Alina Zahid
External view of the U.S. Capitol building
Business
Novo CEO Reluctantly Agrees to Meet With PBMs on Ozempic, Wegovy Prices
In a Tuesday Senate hearing on Novo Nordisk’s drug pricing, CEO Lars Fruergaard Jørgensen said he would be willing to sit down with the three largest pharmacy benefit managers who committed that they would expand coverage of Ozempic and Wegovy if Novo lowers its list prices for the blockbuster drugs.
September 25, 2024
 · 
3 min read
 · 
Greg Slabodkin
IRA
Cancer and Diabetes Drugs Expected to Dominate 2025 Medicare Negotiations Under IRA
Many Big Pharma companies including Pfizer, Merck and BMS make the drugs that some researchers expect to be selected by CMS for next year’s Medicare price negotiations alongside analysts’ top pick, Novo Nordisk’s Ozempic.
September 25, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Merck building and sign in Silicon Valley
Cancer
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
September 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Tampa, Florida
Phase III
Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, But Analysts See Mixed Results
Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the OX40 receptor blocker “came in at the lower end of efficacy and expectations,” but found Uplizna’s performance in generalized myasthenia gravis “better than expected.”
September 25, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of a stomach tumor
Regulatory
FDA Considers Narrowing Label of PD-1 Drugs in Stomach Cancer Ahead of Adcomm Meeting
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed for the first-line treatment of several types of stomach cancer regardless of PD-L1 expression.
September 25, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Approvals
IntraBio Wins FDA Nod for Ultra-Rare Neurodegenerative Disease on Heels of Competitor’s Approval
IntraBio’s Aqneursa is the second drug within a week approved by the regulator for treating Niemann-Pick disease type C, just days behind Zevra Therapeutics’ Miplyffa.
September 25, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS